US2975097A - Topical analgesic composition - Google Patents

Topical analgesic composition Download PDF

Info

Publication number
US2975097A
US2975097A US696052A US69605257A US2975097A US 2975097 A US2975097 A US 2975097A US 696052 A US696052 A US 696052A US 69605257 A US69605257 A US 69605257A US 2975097 A US2975097 A US 2975097A
Authority
US
United States
Prior art keywords
salicylate
compositions
analgesic composition
topical analgesic
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US696052A
Inventor
Modderno John Paul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Modern-Lab Inc
Original Assignee
Modern-Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modern-Lab Inc filed Critical Modern-Lab Inc
Priority to US696052A priority Critical patent/US2975097A/en
Priority to GB34515/58A priority patent/GB900180A/en
Application granted granted Critical
Publication of US2975097A publication Critical patent/US2975097A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/618Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams

Definitions

  • this invention relates to hydrophilic base compositions for topical application having at least one ethyl aminosalicylate, at least one alkyl ester of amino benzoic acid, and at least one chlorinated phenol as the therapeutically active ingredients to effect rapid penetration by the active ingredients into the skin to provide for quick analgesic relief.
  • compositions which by topical application will rapidly alleviate pain, such as rheumatic muscular aches and pains.
  • Many analgesic compositions have been formulated for topical application to relieve rheumatic and muscular and surface aches and pains, but these compositions have the disadvantage of requiring intense rubbing or massaging of the material into the skin, which often produces chafing of the skin, in order to effect penetration of the active ingredient. This lack of rapid penetration of the active pain relieving ingredients prolongs discomfort and delays the desired relief. Where penetration of the active ingredients is resisted by the skin, only a minor pain relieving effect results. Such compositions also require the application of large quantities of the material in order to obtain pain relieving results, which of course causes discomfort to the user.
  • the present invention resides in the discovery of a potentiated topical analgesic composition having rapid tissue penetrating powers to bring about increased effectiveness for the relief of pain. It has been found that the combination of at least one of the mono-, di, and triethylamine salicylates, atleast one alkyl ester of amino benzoic acid, and antibacterial chlorinated phenol provides a potentiated active ingredient which, when incorporated in a hydrophilic base carrier, produces rapid and uniform penetration of the ingredients into the skin and tissue to bring about quick relief from muscular aches and pains of the rheumatic type.
  • the combination of active ingredients of this invention can be incorporated in any type of hydrophilic base, such as an ointment, a cream, a petrochemical base, a base comprised of polymerized resins capable of emulsification, or an aliphatic base. It will be appreciated that these bases act as the carrier of the active ingredients and present a homogeneous medium with the active ingredients thoroughly dispersed therethrough so that application to the body effects uniform medication to the area treated.
  • To the active ingredients and base making up the compositions of this invention can be added minor amounts of other materials, such as parasepts for preventing fungus growth; coolants such as thymol, camphcr, and the like; perfumes; surfactants, and other body treating and soothing compounds.
  • the active ingredients of this invention can be applied as a sprayby incorporating them in a sprayable carrier for treatment of the body,
  • a sprayhuman body from a pressurized dispensing device having the ability to apply the spray in a simple and effective Patented Mar. 14, 1961 manner.
  • a carrier and a dispensing gas which Will produce a non-foaming application of the effective ingredients.
  • a standard pressurized dispensing device may be used to apply the spray to the skin.
  • a very effective gas which minimizes the possibility of foaming, is argon, but it will be appreciated that other types of inert gases may be used. It has been found that argon gas does not form a foamable mixture with the material to be sprayed when it is released from the pressurized container but rather acts like a piston so that the composition is projected for effective application to the skin.
  • the rapid penetration of the amino salicylates is believed to be enhanced by the presence of the chlorinated phenol, which produces a beneficial treatment to the skin and which is an antibacterial compound.
  • compositions of this invention may be in form of a solution or in a hydrophilic base, such as a polymerized resin, cream, ointment, salve, or the like.
  • the principal active analgesic ingredient in the composition is at least one ethyl type aminosalicylate, the mono-, di, or triethylamine salicylates being preferred.
  • the other active ingredients are the local anesthetic alkyl ester of amino benzoic acid, such as the ethyl-para-aminobenzoate (benzocaine), butyl aminobenzoate, piperocaine hydrochloride, and the like, the ethyl-para-aminobenzoate being preferred; and the local antibacterial chlorinated phenols, such as hexachlorophene, p-chlorophenol, chlorothymol, etc, hexachlorophene being preferred.
  • the local anesthetic alkyl ester of amino benzoic acid such as the ethyl-para-aminobenzoate (benzocaine), butyl aminobenzoate, piperocaine hydrochloride, and the like, the ethyl-para-aminobenzoate being preferred
  • the local antibacterial chlorinated phenols such as hexachlorophene, p-chlorophenol, chlorothymol, etc, he
  • the combination of these active ingredients provides for rapid absorption of medication into the tissues of the body upon application as well as antiseptic, antibacterial and germicidal action which brings about the quick effective medication of the skin to which the active ingredients have been applied, as well as the thorough and rapid penetration of the tissues for effective relief.
  • the proportions of the active ingredients depend upon the application desired, excellent results are obtained when the amino salicylate is in the range of 5 to 15 parts by weight, the alkyl amino benzoate in the range of 0.5 to 2 parts by weight, and the chlorinated phenol in the range of 0.1 to 0.5 part by weight.
  • the amino salicylate used in the compositions of this invention can be prepared by the following procedure.
  • Diethylamine salicylate for example, can be prepared by 'reacting stoichiometric quantities of U.S.P. salicylic acid with the niol weight requirement of diethylamine in sufficient water to make a 50% solution. The solution is held at a temperature of 80 C. for three hours in a glass reactor and agitated to insure completion of the reaction and to drive off any excess free amine. The ethylamine by condensation is added onto the carboxyl group of the salicylic acid forming water and diethylamine salicylate.
  • the free amine or free salicylic acid is determined by titration and the identity of the compound is verified by infrared examination and a comparison with standard infrared curves. Purity of the diethylamine salicylate is determined by taking its melting point and analyzing for nitrogen, carbon and hydrogen content. In like manner,
  • the monoethylamine and triethylamine salicylates can be formed by addition of the respective amine to the carboXyl group of salicylic acid under condensation conditions.
  • Example 1 Ten percent by weight of diethylarnine salicylate, 0.5% by weight of monoethylamine salicylate, and 0.5% by weight of triethylamine salicylate together with 1.0% of butyl benzocaine and 0.1% of hexachlorophene to which is added 2.0% of glyceryl stearate, 5.0% of a petroleum base oil, 0.5% of lanolin, 2.0% of Span 40, and 2% of Tween 40 were melted together to form a homogeneous mixture.
  • the batch was mixed until it was paste-like in consistency and then 70.9% by weight of water, 5% by weight of glycerol, 0.5 by weight sodium alginate as a protective colloid, and a modicum of perfume were added. The mixing was continued until a creamlike base was formed having the active ingredients thoroughly dispersed therethrough.
  • composition thus prepared when applied to the skin was found to produce rapid alleviation of rheumatic and arthritic pain.
  • Example II The formulation as set forth in Example I was prepared except that 69.8% of water was used and 0.1% of a propyl parasept was included in the melt to introduce into the medicated composition fungicidal properties. When the medicated cream was applied to the skin, it was found to rapidly reduce rheumatic aches and pains.
  • Example III Ten percent by weight of diethylaminc salicylate, 0.5% by weight of monoethylamine salicylate, and 0.5% by weight of triethylamine salicylate together with 1.0% of benzocaine and 2.0% of hexachlorophene to which is added 2.0% of a petroleum base oil, 0.5% lanolin, 2.0% of Span 40, 2.0% of Tween 40, 0.3% of thymol, 0.3% of menthol, and 0.3% of camphor were melted together to form a homogeneous mixture. The batch was mixed until it was pastelike in consistency. To the melt was added 68.5% by weight of an 80% isopropanol, 5.0%
  • Antara CO-630 emulsifier 0.0% glycerine
  • the analgesic composition was placed in an aerosol container, pressurized, and upon spraying on the feet, was found to produce a rapid alleviation of pain normal to tired feet.
  • the spray was also found to inhibit effectively fungicidal growth occasioned by the disease known as athletes foot.
  • Tween 40 and Span 40 were employed.
  • Tween 40 is an emulsifying, wetting, dispersing, and detergent agent produced and sold by Atlas Powder Company and is listed in their trade catalog as a polyoxyalkylene ether of partial palmitic acid ester.
  • Span 40 is also an Atlas Powder Company product sold as an emulsifying agent and is described as sorbitan monopalmitate.
  • other minor ingredients used to formulate the compositions of this invention are well-known and their names have become accepted in the art.
  • compositions of this invention may be incorporated in the compositions of this invention to produce a variety of effects on the skin of the user or to affect the degree of emulsification, surfactant properties, etc.
  • the percentage of the various amino salicylates may be varied to produce the same or equivalent results, or that one or more of the amino salicylates may be used.
  • compositions made in accordance with Examples I and III in which the salicylates varied from 5% to 15% pro- All of the **d excellent results in the relief of pain, as heretofore described The amount of benzocaine or its equivalent, when varied from 0.5 to 2.0% in the compositions of this invention, also provides instant relief of pain.
  • the hexachlorophenc when varied from 0.1% to 0.5% produces the same or equivalent results.
  • the percentages of the various additive ingredients may be varied to produce the desired effects depending upon the degree of surface activity required in the composition.
  • isopropyl alcohol used as the major constituent in the therapeutic carrier of the foot analgesic composition, it has been found that other alcohols having like properties may be used to form the base for carrying the medication.
  • a topical analgesic composition comprising a hydrophilic carrier and a therapeutically active ingredient formed essentially from at least one aminosalicylate selected from the group consisting of monoethylamine salicylate, diethylamine salicylate, and triethylamine salicylate, at least one alkyl ester of amino benzoic acid, and at least one antibacterial chlorinated phenol.
  • topical analgesic composition claim 4 in which the major portion of isopropyl alcohol.
  • Asprayable topical analgesic composition comprising a liquid hydrophilic carrier having dispersed therethrough at least one aminosalicylate selected from the group consisting of mono-, di-, and triethylaminc salicylates, at least one alkyl ester of amino benzoic acid, at least one antibacterial chlorinated phenol and a propellent gas.

Description

United States Patent 2,975,097 TOPICAL ANALGESIC COMPOSITION John Paul Modderno, Gambrills, Md., assignor to Modern-Lab, Incorporated, Baltimore, Md., a corporation of Maryland No Drawing. Filed Nov. 13, 1957, Ser. No. 696,052 9 Claims. (Cl. 167-52) This invention relates to topical analgesic compositions for rapid relief of muscular aches and pain. More particularly, this invention relates to hydrophilic base compositions for topical application having at least one ethyl aminosalicylate, at least one alkyl ester of amino benzoic acid, and at least one chlorinated phenol as the therapeutically active ingredients to effect rapid penetration by the active ingredients into the skin to provide for quick analgesic relief.
The search for more effective topical analgesic agents than those known at present is a never-ending one. Efforts are constantly being made to find compositions which by topical application will rapidly alleviate pain, such as rheumatic muscular aches and pains. Many analgesic compositions have been formulated for topical application to relieve rheumatic and muscular and surface aches and pains, but these compositions have the disadvantage of requiring intense rubbing or massaging of the material into the skin, which often produces chafing of the skin, in order to effect penetration of the active ingredient. This lack of rapid penetration of the active pain relieving ingredients prolongs discomfort and delays the desired relief. Where penetration of the active ingredients is resisted by the skin, only a minor pain relieving effect results. Such compositions also require the application of large quantities of the material in order to obtain pain relieving results, which of course causes discomfort to the user.
The present invention resides in the discovery of a potentiated topical analgesic composition having rapid tissue penetrating powers to bring about increased effectiveness for the relief of pain. It has been found that the combination of at least one of the mono-, di, and triethylamine salicylates, atleast one alkyl ester of amino benzoic acid, and antibacterial chlorinated phenol provides a potentiated active ingredient which, when incorporated in a hydrophilic base carrier, produces rapid and uniform penetration of the ingredients into the skin and tissue to bring about quick relief from muscular aches and pains of the rheumatic type.
The combination of active ingredients of this invention can be incorporated in any type of hydrophilic base, such as an ointment, a cream, a petrochemical base, a base comprised of polymerized resins capable of emulsification, or an aliphatic base. It will be appreciated that these bases act as the carrier of the active ingredients and present a homogeneous medium with the active ingredients thoroughly dispersed therethrough so that application to the body effects uniform medication to the area treated. To the active ingredients and base making up the compositions of this invention can be added minor amounts of other materials, such as parasepts for preventing fungus growth; coolants such as thymol, camphcr, and the like; perfumes; surfactants, and other body treating and soothing compounds.
It has also been found that the active ingredients of this invention can be applied as a sprayby incorporating them in a sprayable carrier for treatment of the body,
For this type of application, a sprayhuman body from a pressurized dispensing device having the ability to apply the spray in a simple and effective Patented Mar. 14, 1961 manner. In this type of applicator, it is particularly desirable to have a carrier and a dispensing gas which Will produce a non-foaming application of the effective ingredients. A standard pressurized dispensing device may be used to apply the spray to the skin. It has been found that a very effective gas, which minimizes the possibility of foaming, is argon, but it will be appreciated that other types of inert gases may be used. It has been found that argon gas does not form a foamable mixture with the material to be sprayed when it is released from the pressurized container but rather acts like a piston so that the composition is projected for effective application to the skin.
There are instances'in which the combined action of two or more drugs is greater than that which can be anticipated from the sum of their individual actions, commonly referred to as potentiation, as set forth by Louis S. Goodman and Alfred Gilman on page ll'of their book The Pharmacological Basis of Therapeutics, 2nd ed., Macmillan Company, New York, 1956. It is believed that the rapidity of pain relief efiected by the compositions of this invention is the result of potentiation.
The rapid penetration of the amino salicylates is believed to be enhanced by the presence of the chlorinated phenol, which produces a beneficial treatment to the skin and which is an antibacterial compound.
These and other objects and advantages will become apparent from an examination of the following description and appended claims.
The compositions of this invention may be in form of a solution or in a hydrophilic base, such as a polymerized resin, cream, ointment, salve, or the like. The principal active analgesic ingredient in the composition is at least one ethyl type aminosalicylate, the mono-, di, or triethylamine salicylates being preferred. The other active ingredients are the local anesthetic alkyl ester of amino benzoic acid, such as the ethyl-para-aminobenzoate (benzocaine), butyl aminobenzoate, piperocaine hydrochloride, and the like, the ethyl-para-aminobenzoate being preferred; and the local antibacterial chlorinated phenols, such as hexachlorophene, p-chlorophenol, chlorothymol, etc, hexachlorophene being preferred. The combination of these active ingredients provides for rapid absorption of medication into the tissues of the body upon application as well as antiseptic, antibacterial and germicidal action which brings about the quick effective medication of the skin to which the active ingredients have been applied, as well as the thorough and rapid penetration of the tissues for effective relief.
Although the proportions of the active ingredients depend upon the application desired, excellent results are obtained when the amino salicylate is in the range of 5 to 15 parts by weight, the alkyl amino benzoate in the range of 0.5 to 2 parts by weight, and the chlorinated phenol in the range of 0.1 to 0.5 part by weight.
The amino salicylate used in the compositions of this invention can be prepared by the following procedure. Diethylamine salicylate, for example, can be prepared by 'reacting stoichiometric quantities of U.S.P. salicylic acid with the niol weight requirement of diethylamine in sufficient water to make a 50% solution. The solution is held at a temperature of 80 C. for three hours in a glass reactor and agitated to insure completion of the reaction and to drive off any excess free amine. The ethylamine by condensation is added onto the carboxyl group of the salicylic acid forming water and diethylamine salicylate.
The free amine or free salicylic acid is determined by titration and the identity of the compound is verified by infrared examination and a comparison with standard infrared curves. Purity of the diethylamine salicylate is determined by taking its melting point and analyzing for nitrogen, carbon and hydrogen content. In like manner,
the monoethylamine and triethylamine salicylates can be formed by addition of the respective amine to the carboXyl group of salicylic acid under condensation conditions.
The following examples are by way of illustration and are not to be considered in any way a limitation of the scope of the compositions forming a part of the invention:
Example 1 Ten percent by weight of diethylarnine salicylate, 0.5% by weight of monoethylamine salicylate, and 0.5% by weight of triethylamine salicylate together with 1.0% of butyl benzocaine and 0.1% of hexachlorophene to which is added 2.0% of glyceryl stearate, 5.0% of a petroleum base oil, 0.5% of lanolin, 2.0% of Span 40, and 2% of Tween 40 were melted together to form a homogeneous mixture. The batch was mixed until it was paste-like in consistency and then 70.9% by weight of water, 5% by weight of glycerol, 0.5 by weight sodium alginate as a protective colloid, and a modicum of perfume were added. The mixing was continued until a creamlike base was formed having the active ingredients thoroughly dispersed therethrough.
The composition thus prepared, when applied to the skin was found to produce rapid alleviation of rheumatic and arthritic pain.
Example II The formulation as set forth in Example I was prepared except that 69.8% of water was used and 0.1% of a propyl parasept was included in the melt to introduce into the medicated composition fungicidal properties. When the medicated cream was applied to the skin, it was found to rapidly reduce rheumatic aches and pains.
Example III Ten percent by weight of diethylaminc salicylate, 0.5% by weight of monoethylamine salicylate, and 0.5% by weight of triethylamine salicylate together with 1.0% of benzocaine and 2.0% of hexachlorophene to which is added 2.0% of a petroleum base oil, 0.5% lanolin, 2.0% of Span 40, 2.0% of Tween 40, 0.3% of thymol, 0.3% of menthol, and 0.3% of camphor were melted together to form a homogeneous mixture. The batch was mixed until it was pastelike in consistency. To the melt was added 68.5% by weight of an 80% isopropanol, 5.0%
by weight Antara CO-630 emulsifier, 5.0% glycerine,
and 0.1% of a propyl parasept. Stirring of the solution continued until the melt was thoroughly mixed. The analgesic composition was placed in an aerosol container, pressurized, and upon spraying on the feet, was found to produce a rapid alleviation of pain normal to tired feet. The spray was also found to inhibit effectively fungicidal growth occasioned by the disease known as athletes foot.
In order to emulsify the compositions of this invention, Tween 40 and Span 40 were employed. Tween 40 is an emulsifying, wetting, dispersing, and detergent agent produced and sold by Atlas Powder Company and is listed in their trade catalog as a polyoxyalkylene ether of partial palmitic acid ester. Span 40 is also an Atlas Powder Company product sold as an emulsifying agent and is described as sorbitan monopalmitate. other minor ingredients used to formulate the compositions of this invention are well-known and their names have become accepted in the art.
It will be understood that many non-active ingredients other than those illustrated above may be incorporated in the compositions of this invention to produce a variety of effects on the skin of the user or to affect the degree of emulsification, surfactant properties, etc.
It will be appreciated that the percentage of the various amino salicylates may be varied to produce the same or equivalent results, or that one or more of the amino salicylates may be used. For example, it was found that compositions made in accordance with Examples I and III in which the salicylates varied from 5% to 15% pro- All of the duced excellent results in the relief of pain, as heretofore described. The amount of benzocaine or its equivalent, when varied from 0.5 to 2.0% in the compositions of this invention, also provides instant relief of pain. In like manner, the hexachlorophenc, when varied from 0.1% to 0.5% produces the same or equivalent results.
It will be appreciated that the percentages of the various additive ingredients, such as the coolants, surfactants, and fungicides (parasepts), may be varied to produce the desired effects depending upon the degree of surface activity required in the composition. In the case of the use of isopropyl alcohol, used as the major constituent in the therapeutic carrier of the foot analgesic composition, it has been found that other alcohols having like properties may be used to form the base for carrying the medication.
In view of the invention presented herein, it will be appreciated that various modifications to the compositions may be made depending on the individual or particular needs, and it is understood that all compositions having the active ingredients as set forth and contained in the appended claims fall within the spirit and scope of this invention.
What is claimed is:
1. A topical analgesic composition comprising a hydrophilic carrier and a therapeutically active ingredient formed essentially from at least one aminosalicylate selected from the group consisting of monoethylamine salicylate, diethylamine salicylate, and triethylamine salicylate, at least one alkyl ester of amino benzoic acid, and at least one antibacterial chlorinated phenol.
2. The topical analgesic composition as claimed in claim 1 in which the alkyl ester of amino benzoic acid is ethyl-para-aminobenzoate.
3. The topical analgesic composition as claimed in claim 1 in which the antibacterial chlorinated phenol is hexachlorophene.
4. The topical analgesic composition as claimed in claim 1 in which a major portion by weight of said carrier is a hydrophilic alcohol.
5. The topical analgesic composition claim 4 in which the major portion of isopropyl alcohol.
6. The topical analgesic composition as claimed in claim 1 in which said carrier is in an emulsified form.
7. Asprayable topical analgesic composition comprising a liquid hydrophilic carrier having dispersed therethrough at least one aminosalicylate selected from the group consisting of mono-, di-, and triethylaminc salicylates, at least one alkyl ester of amino benzoic acid, at least one antibacterial chlorinated phenol and a propellent gas.
8. The sprayable topical analgesic composition as claimed in claim 7 in which the propellent gas is an inert gas.
9. The sprayable topical analgesic composition as claimed in claim 7 in which the propellent gas is argon.
as claimed in said carrier is References Cited in the file of this patent UNITED STATES PATENTS 1,531,464 Wallis Mar. 31, 1925 2,045,125 Curtis June 23, 1936 2,105,197 McCrea Jan. 11, 1938 2,457,188 Stone Dec. 28, 1948 2,782,975 Bird Feb. 26, 1957 2,801,201 Kipnis July 30, 1957 FOREIGN PATENTS 716,481 Great Britain Oct. 6, 1954 OTHER REFERENCES Ellin et al.: J.A.P.A., Prac. Pharm. Ed., vol. 16, No. 12, December 1955, pp. 747-749.
I.A.M.A., vol. 160, No. 17, April 28, 1956, p. 101.
Dispensatory of U.S., 25th ed. (1955), Lippincott Co., Philadelphia, pp. 640-641.

Claims (1)

1. A TOPICAL ANALGESIC COMPOSITION COMPRISING A HYDROPHILIC CARRIER AND A THERAPEUTICALLY ACTIVE INGREDIENT FORMED ESSENTIALLY FROM AT LEAST ONE AMINOSALICYLATE SELECTED FROM THE GROUP CONSISTING OF MONOETHYLAMINE SALICYLATE, DIETHYLAMINE SALICYLATE, AND TRIETHYLAMINE SALICYLATE, AT LEAST ONE ALKYL ESTER OF AMINO BENZOIC ACID, AND AT LEAST ONE ANTIBACTERIAL CHLORINATED PHENOL.
US696052A 1957-11-13 1957-11-13 Topical analgesic composition Expired - Lifetime US2975097A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US696052A US2975097A (en) 1957-11-13 1957-11-13 Topical analgesic composition
GB34515/58A GB900180A (en) 1957-11-13 1958-10-28 Topical analgesic compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US696052A US2975097A (en) 1957-11-13 1957-11-13 Topical analgesic composition

Publications (1)

Publication Number Publication Date
US2975097A true US2975097A (en) 1961-03-14

Family

ID=24795517

Family Applications (1)

Application Number Title Priority Date Filing Date
US696052A Expired - Lifetime US2975097A (en) 1957-11-13 1957-11-13 Topical analgesic composition

Country Status (2)

Country Link
US (1) US2975097A (en)
GB (1) GB900180A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294635A (en) * 1962-09-26 1966-12-27 Merck E 3, 4-dihydro-benzoxazinones-(1, 3, 2) as an analgesic agent
US3300532A (en) * 1959-06-26 1967-01-24 Donau Pharmazie Gmbh Nu-(beta-diethylamino ethyl)-nu-[beta-hydroxy-beta-(phenyl) ethyl] anilines and salts thereof
US3368937A (en) * 1965-01-26 1968-02-13 Merck & Co Inc Injectable solid steroid-anesthetic
US3859432A (en) * 1967-10-24 1975-01-07 Ben Dinerstein Method for soothing cooling and refreshing
US4199576A (en) * 1976-12-15 1980-04-22 The Procter & Gamble Company Analgesic and anti-inflammatory compositions for topical application
US4560549A (en) * 1983-08-24 1985-12-24 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4590212A (en) * 1981-12-09 1986-05-20 Soft Sheen Products, Inc. Method of increasing the rate of wound healing and composition
US4725590A (en) * 1983-08-24 1988-02-16 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
AU685741B2 (en) * 1992-12-04 1998-01-29 Mayor Pharmaceutical Laboratories, Inc. Sprayable analgesic composition and method of use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1531464A (en) * 1925-03-31 Bignob to atmostebol
US2045125A (en) * 1935-10-19 1936-06-23 Curtis David Anesthetic solutions
US2105197A (en) * 1931-07-13 1938-01-11 Parke Davis & Co Medicament
US2457188A (en) * 1945-05-24 1948-12-28 Americaine Inc Benzocaine solution
GB716481A (en) * 1947-12-23 1954-10-06 Olivier Gaudin Preparation of organic salts
US2782975A (en) * 1955-04-20 1957-02-26 American Cyanamid Co Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing
US2801201A (en) * 1953-04-09 1957-07-30 Lincoln Lab Inc Burn treatment filling for pressure packaged dispenser

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1531464A (en) * 1925-03-31 Bignob to atmostebol
US2105197A (en) * 1931-07-13 1938-01-11 Parke Davis & Co Medicament
US2045125A (en) * 1935-10-19 1936-06-23 Curtis David Anesthetic solutions
US2457188A (en) * 1945-05-24 1948-12-28 Americaine Inc Benzocaine solution
GB716481A (en) * 1947-12-23 1954-10-06 Olivier Gaudin Preparation of organic salts
US2801201A (en) * 1953-04-09 1957-07-30 Lincoln Lab Inc Burn treatment filling for pressure packaged dispenser
US2782975A (en) * 1955-04-20 1957-02-26 American Cyanamid Co Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300532A (en) * 1959-06-26 1967-01-24 Donau Pharmazie Gmbh Nu-(beta-diethylamino ethyl)-nu-[beta-hydroxy-beta-(phenyl) ethyl] anilines and salts thereof
US3294635A (en) * 1962-09-26 1966-12-27 Merck E 3, 4-dihydro-benzoxazinones-(1, 3, 2) as an analgesic agent
US3368937A (en) * 1965-01-26 1968-02-13 Merck & Co Inc Injectable solid steroid-anesthetic
US3859432A (en) * 1967-10-24 1975-01-07 Ben Dinerstein Method for soothing cooling and refreshing
US4199576A (en) * 1976-12-15 1980-04-22 The Procter & Gamble Company Analgesic and anti-inflammatory compositions for topical application
US4590212A (en) * 1981-12-09 1986-05-20 Soft Sheen Products, Inc. Method of increasing the rate of wound healing and composition
US4560549A (en) * 1983-08-24 1985-12-24 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4725590A (en) * 1983-08-24 1988-02-16 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
AU685741B2 (en) * 1992-12-04 1998-01-29 Mayor Pharmaceutical Laboratories, Inc. Sprayable analgesic composition and method of use

Also Published As

Publication number Publication date
GB900180A (en) 1962-07-04

Similar Documents

Publication Publication Date Title
RU2754846C1 (en) Local anaesthetic compositions
JP4057234B2 (en) Foam skin cream, use of foam skin protection cream and method for producing the same
US5869533A (en) Non-irritating capsaicin formulations and applicators therefor
US2975097A (en) Topical analgesic composition
US20050075407A1 (en) Foam incorporating eutetic mixture
US5543148A (en) Stick delivery system for topical application of a treatment agent
JP2000504697A (en) Skin penetration enhancer and drug delivery system containing the same
IE45321B1 (en) Sprayable germicidal foam compositions
JPH0215023A (en) Anesthetic/skin humidifying composition and production thereof
US6818671B1 (en) Nimesulide containing topical pharmaceutical compositions
CA2726538A1 (en) Foam skin care cream
US4062937A (en) Insect bite relief preparation
JPS6061518A (en) Gelatinous external composition
US5176918A (en) Topical medicament
US11045483B2 (en) Pain-killing composition comprising a salicylic acid derivative
AU768917B2 (en) Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues
JPH04103526A (en) Aerosol for skin cooling
EP1647282A1 (en) Topical anti-inflammatory aqueous gel containing menthol, thymol and eucalyptol, process for their preparation and use of thereof
JP4450545B2 (en) Aerosol formulation
JP3338877B2 (en) Spray for pruritic skin disease
US3352753A (en) Pharmaceutical compositions of corticosteroids in gelled alcohol
US3340148A (en) Treatment of fungus diseases of the skin
US1870107A (en) Medicated ointment composition
JP3027838B2 (en) Eyazole composition
US3152951A (en) Germicidal composition of iodine and liquid lanolin